Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.

Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.